Figure 2.

(A) Averaged contraction data from saline- or lipopolysaccharide-treated mouse myocytes in the presence of cyclopentyladenosine (CPA) (1 µmol/L), H89 (1 µmol/L), or co-treatment with both CPA and H89 (n = 80–100 cells from three hearts; *P < 0.01) and (B) maximum shortening velocity (V_max, µm/s). (C and D) Representative traces for single cells showing the effect of co-treatment with both CPA and H89 for 10 min on a control (C) and septic cell (D). (E) Amplitude of Ca²⁺-transients (Indo-1 410/480 ratio) and RT₅₀ (ms) of Ca²⁺-transients in the presence of (F) CPA or (G) H89. Bars represent mean ± SE of the mean.